FindTrial
Sign In

A survey on the adverse reactions of SARS-CoV-2 vaccine in patients with inflammatory bowel disease

A survey on the adverse reactions of SARS-CoV-2 vaccine in patients with inflammatory bowel disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0006839
Enrollment
600
Registered
2021-12-17
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Keimyung University Dongsan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patient group: IBD patients aged between 20 and 80 years, who have been inoculated with second SARS-CoV-2 vaccine for more than 1 week 2. Health control group: Persons aged between 20 and 80 who have been inoculated with second SARS-CoV-2 vaccine for more than 1 week 3. A participant who has signed a written consent form after hearing the explanation of the purpose and method of the clinical research

Exclusion criteria

Exclusion criteria: 1. Patient group: Patients with IBD for whom information on adverse reactions related to vaccination cannot be obtained 2. Healthy control group: Healthcare workers for whom information on adverse reactions related to vaccination cannot be obtained 3. IBD patients with acute illness who have been hospitalized within 4 weeks of vaccination 4. IBD patients who have had surgery within 3 months 5. Subjects who do not agree to participate in the study

Design outcomes

Primary

MeasureTime frame
Vaccine-related adverse events—

Secondary

MeasureTime frame
IBD-related symptoms—

Countries

Korea, Republic of

Contacts

Public ContactJeongseok Kim

Keimyung University Dongsan Hospital

nobeldoc@gmail.com+82-53-258-7762

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026